🚀 VC round data is live in beta, check it out!
Jointown Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Jointown Pharmaceutical and similar public comparables like CR Pharmaceutical, Sugi Holdings, COSMOS Pharmaceutical, Nahdi Medical and more.
Jointown Pharmaceutical Overview
About Jointown Pharmaceutical
Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and mainly serves medical institutions, wholesale enterprises, and retail pharmacies.
Founded
1999
HQ
Employees
30.2K
Website
Sectors
Financials (LTM)
EV
$4B
Jointown Pharmaceutical Financials
Jointown Pharmaceutical reported last 12-month revenue of $24B and EBITDA of $713M.
In the same LTM period, Jointown Pharmaceutical generated $1B in gross profit, $713M in EBITDA, and $370M in net income.
Revenue (LTM)
Jointown Pharmaceutical P&L
In the most recent fiscal year, Jointown Pharmaceutical reported revenue of $22B and EBITDA of $839M.
Jointown Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $24B | XXX | $22B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 6% | XXX | 8% | XXX | XXX | XXX |
| EBITDA | $713M | XXX | $839M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 4% | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $370M | XXX | $364M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Jointown Pharmaceutical Stock Performance
Jointown Pharmaceutical has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Jointown Pharmaceutical's stock price is $0.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 1.0% | XXX | XXX | XXX | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJointown Pharmaceutical Valuation Multiples
Jointown Pharmaceutical trades at 0.2x EV/Revenue multiple, and 5.2x EV/EBITDA.
EV / Revenue (LTM)
Jointown Pharmaceutical Financial Valuation Multiples
As of March 19, 2026, Jointown Pharmaceutical has market cap of $4B and EV of $4B.
Equity research analysts estimate Jointown Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jointown Pharmaceutical has a P/E ratio of 10.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 4.4x | XXX | XXX | XXX |
| EV/EBIT | 6.3x | XXX | 6.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.6x | XXX | 2.2x | XXX | XXX | XXX |
| P/E | 10.2x | XXX | 10.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 12.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jointown Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Jointown Pharmaceutical Margins & Growth Rates
Jointown Pharmaceutical's revenue in the last 12 month grew by 6%.
Jointown Pharmaceutical's revenue per employee in the last FY averaged $0.8M.
Jointown Pharmaceutical's rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jointown Pharmaceutical's rule of X is 18% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Jointown Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | (16%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 9% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 18% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 5% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Jointown Pharmaceutical Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CR Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sugi Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| COSMOS Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Nahdi Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Yifeng Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jointown Pharmaceutical M&A Activity
Jointown Pharmaceutical acquired XXX companies to date.
Last acquisition by Jointown Pharmaceutical was on XXXXXXXX, XXXXX. Jointown Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Jointown Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJointown Pharmaceutical Investment Activity
Jointown Pharmaceutical invested in XXX companies to date.
Jointown Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Jointown Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Jointown Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jointown Pharmaceutical
| When was Jointown Pharmaceutical founded? | Jointown Pharmaceutical was founded in 1999. |
| Where is Jointown Pharmaceutical headquartered? | Jointown Pharmaceutical is headquartered in China. |
| How many employees does Jointown Pharmaceutical have? | As of today, Jointown Pharmaceutical has over 30K employees. |
| Is Jointown Pharmaceutical publicly listed? | Yes, Jointown Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Jointown Pharmaceutical? | Jointown Pharmaceutical trades under 600998 ticker. |
| When did Jointown Pharmaceutical go public? | Jointown Pharmaceutical went public in 2010. |
| Who are competitors of Jointown Pharmaceutical? | Jointown Pharmaceutical main competitors are CR Pharmaceutical, Sugi Holdings, COSMOS Pharmaceutical, Nahdi Medical. |
| What is the current market cap of Jointown Pharmaceutical? | Jointown Pharmaceutical's current market cap is $4B. |
| What is the current revenue of Jointown Pharmaceutical? | Jointown Pharmaceutical's last 12 months revenue is $24B. |
| What is the current revenue growth of Jointown Pharmaceutical? | Jointown Pharmaceutical revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Jointown Pharmaceutical? | Current revenue multiple of Jointown Pharmaceutical is 0.2x. |
| Is Jointown Pharmaceutical profitable? | Yes, Jointown Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jointown Pharmaceutical? | Jointown Pharmaceutical's last 12 months EBITDA is $713M. |
| What is Jointown Pharmaceutical's EBITDA margin? | Jointown Pharmaceutical's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Jointown Pharmaceutical? | Current EBITDA multiple of Jointown Pharmaceutical is 5.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.